|
Parameters
|
Group A
|
Group B
|
P value
|
|---|
| |
(MMC+Gemcitabine)
|
(MMC)
| |
|---|
|
Total patients
|
102
|
96
|
NS+
|
|
Male
|
81
|
78
|
NS+
|
|
Female
|
21
|
19
|
NS+
|
|
Age
|
65.7±9.8 yrs
|
63.9±8.9 yrs
|
NS+
|
|
Mean Duration of follow up
|
36 months
|
36 months
| |
|
Mean size of tumor <2cm
|
63
|
58
|
NS+
|
|
Mean sixe of tume >2 cm
|
39
|
38
|
NS+
|
|
Stage Ta
|
60
|
58
|
NS+
|
|
Stage T1
|
42
|
38
|
NS+
|
|
Grade 1
|
19
|
17
|
NS+
|
|
Grade 2
|
63
|
61
|
NS+
|
|
Grade 3
|
20
|
18
|
NS+
|
|
Previous treatment with BCG
|
All
|
All
| |
|
Aim of complete response
|
100%
|
100%
| |
|
Actual complete response
|
83.67% (82)
|
65.6% (63)
|
0.001*
|
|
Recurrence %
|
12.2% (12)
|
25.3% (16)
|
0.001*
|
|
Recurrence
|
22±6.16 months
|
14.5±8.26 months
|
0.001*
|
|
Recurrence range in months
|
8-36 months
|
4-14 months
| |
- Values are presented as mean (+/- standard devitation)
- Group A: Gemcitabine & Mitomycin (MMC+Gentamycin)
- Group B: Mitomycin C(MMS)
- *Statistical significance was analyzed by student t-test
- +Statistical significance was analyzed by the chi-square test.
